BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yu L, Chen S. Toll-like receptors expressed in tumor cells: targets for therapy. Cancer Immunol Immunother. 2008;57:1271-1278. [PMID: 18256828 DOI: 10.1007/s00262-008-0459-8] [Cited by in Crossref: 81] [Cited by in F6Publishing: 82] [Article Influence: 5.8] [Reference Citation Analysis]
Number Citing Articles
1 Jang GY, Lee JW, Kim YS, Lee SE, Han HD, Hong KJ, Kang TH, Park YM. Interactions between tumor-derived proteins and Toll-like receptors. Exp Mol Med 2020;52:1926-35. [PMID: 33299138 DOI: 10.1038/s12276-020-00540-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
2 Gandhi A, Moorthy B, Ghose R. Drug disposition in pathophysiological conditions. Curr Drug Metab. 2012;13:1327-1344. [PMID: 22746301 DOI: 10.2174/138920012803341302] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 6.1] [Reference Citation Analysis]
3 Nourizadeh M, Masoumi F, Memarian A, Alimoghaddam K, Moazzeni SM, Yaghmaie M, Hadjati J. In vitro induction of potent tumor-specific cytotoxic T lymphocytes using TLR agonist-activated AML-DC. Target Oncol 2014;9:225-37. [PMID: 23852664 DOI: 10.1007/s11523-013-0285-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
4 Qiu F, Maniar A, Diaz MQ, Chapoval AI, Medvedev AE. Activation of cytokine-producing and antitumor activities of natural killer cells and macrophages by engagement of Toll-like and NOD-like receptors. Innate Immun 2011;17:375-87. [PMID: 20682587 DOI: 10.1177/1753425910372000] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
5 Quirino MG, Macedo LC, Pagnano KBB, Pagliarini-E-Silva S, Sell AM, Visentainer JEL. Toll-like receptor gene polymorphisms in patients with myeloproliferative neoplasms. Mol Biol Rep 2021;48:4995-5001. [PMID: 34191235 DOI: 10.1007/s11033-021-06238-8] [Reference Citation Analysis]
6 Koido S, Homma S, Okamoto M, Namiki Y, Takakura K, Uchiyama K, Kajihara M, Ohkusa T, Gong J, Tajiri H. The combination of TLR2 and TLR4 agonists promotes the immunogenicity of dendritic cell/cancer cell fusions. Oncoimmunology 2013;2:e24660. [PMID: 24073361 DOI: 10.4161/onci.24660] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
7 Ouyang X, Duan H, Jin Q, Luo X, Han L, Zhao B, Li J, Chen Y, Lin Y, Liu Y, Huang Y, Shuang S, Huang C, He R, Yao Q, Xue Y, Guo S, Zhao J. Moxibustion may delay the aging process of Wistar rats by regulating intestinal microbiota. Biomed Pharmacother 2021;146:112147. [PMID: 34810050 DOI: 10.1016/j.biopha.2021.112147] [Reference Citation Analysis]
8 Zhou GY, Yi YX, Jin LX, Lin W, Fang PP, Lin XZ, Zheng Y, Pan CW. The protective effect of juglanin on fructose-induced hepatitis by inhibiting inflammation and apoptosis through TLR4 and JAK2/STAT3 signaling pathways in fructose-fed rats. Biomed Pharmacother 2016;81:318-28. [PMID: 27261609 DOI: 10.1016/j.biopha.2016.04.013] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 5.0] [Reference Citation Analysis]
9 Zhou M, Mcfarland-mancini MM, Funk HM, Husseinzadeh N, Mounajjed T, Drew AF. Toll-like receptor expression in normal ovary and ovarian tumors. Cancer Immunol Immunother 2009;58:1375-85. [DOI: 10.1007/s00262-008-0650-y] [Cited by in Crossref: 98] [Cited by in F6Publishing: 95] [Article Influence: 7.5] [Reference Citation Analysis]
10 Goutagny N, Estornes Y, Hasan U, Lebecque S, Caux C. Targeting pattern recognition receptors in cancer immunotherapy. Target Oncol 2012;7:29-54. [PMID: 22399234 DOI: 10.1007/s11523-012-0213-1] [Cited by in Crossref: 65] [Cited by in F6Publishing: 60] [Article Influence: 6.5] [Reference Citation Analysis]
11 De Schutter T, Andrei G, Topalis D, Duraffour S, Mitera T, van den Oord J, Matthys P, Snoeck R. Reduced tumorigenicity and pathogenicity of cervical carcinoma SiHa cells selected for resistance to cidofovir. Mol Cancer 2013;12:158. [PMID: 24325392 DOI: 10.1186/1476-4598-12-158] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
12 Yang X, Chen GT, Wang YQ, Xian S, Zhang L, Zhu SM, Pan F, Cheng YX. TLR4 promotes the expression of HIF-1α by triggering reactive oxygen species in cervical cancer cells in vitro-implications for therapeutic intervention. Mol Med Rep 2018;17:2229-38. [PMID: 29207048 DOI: 10.3892/mmr.2017.8108] [Cited by in Crossref: 4] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
13 So EY, Ouchi T. The application of Toll like receptors for cancer therapy. Int J Biol Sci 2010;6:675-81. [PMID: 21060729 DOI: 10.7150/ijbs.6.675] [Cited by in Crossref: 75] [Cited by in F6Publishing: 73] [Article Influence: 6.3] [Reference Citation Analysis]
14 Sajadian A, Tabarraei A, Soleimanjahi H, Fotouhi F, Gorji A, Ghaemi A. Comparing the effect of Toll-like receptor agonist adjuvants on the efficiency of a DNA vaccine. Arch Virol 2014;159:1951-60. [PMID: 24573220 DOI: 10.1007/s00705-014-2024-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
15 Mokhtari Y, Pourbagheri-Sigaroodi A, Zafari P, Bagheri N, Ghaffari SH, Bashash D. Toll-like receptors (TLRs): An old family of immune receptors with a new face in cancer pathogenesis. J Cell Mol Med 2021;25:639-51. [PMID: 33336901 DOI: 10.1111/jcmm.16214] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
16 Mallick R, Duttaroy AK. Can interruption of innate immune recognition-mediated emergency myelopoiesis impede tumor progression? Med Hypotheses 2021;155:110663. [PMID: 34403869 DOI: 10.1016/j.mehy.2021.110663] [Reference Citation Analysis]
17 Słotwiński R, Dąbrowska A, Lech G, Słodkowski M, Słotwińska SM. Gene expression disorders of innate antibacterial signaling pathway in pancreatic cancer patients: implications for leukocyte dysfunction and tumor progression. Cent Eur J Immunol 2014;39:498-507. [PMID: 26155170 DOI: 10.5114/ceji.2014.47736] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
18 Banescu C, Tripon F, Bojan AS, Trifa AP, Muntean C, Crauciuc GA, Boglis A, Candea M, Lazar E, Jimbu L, Iancu M. Association of TLR4 Rs4986791 Polymorphism and TLR9 Haplotypes with Acute Myeloid Leukemia Susceptibility: A Case-Control Study of Adult Patients. JPM 2022;12:409. [DOI: 10.3390/jpm12030409] [Reference Citation Analysis]
19 Zhao B, Niu X, Huang S, Yang J, Wei Y, Wang X, Wang J, Wang Y, Guo X, Urzua U. TLR4 Agonist and Hypoxia Synergistically Promote the Formation of TLR4/NF-κB/HIF-1α Loop in Human Epithelial Ovarian Cancer. Analytical Cellular Pathology 2022;2022:1-19. [DOI: 10.1155/2022/4201262] [Reference Citation Analysis]
20 Zhu G, Cheng Z, Lin C, Hoffman RM, Huang Y, Singh SR, Zheng W, Yang S, Ye J. MyD88 Regulates LPS-induced NF-ĸB/MAPK Cytokines and Promotes Inflammation and Malignancy in Colorectal Cancer Cells. Cancer Genomics Proteomics 2019;16:409-19. [PMID: 31659096 DOI: 10.21873/cgp.20145] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
21 Cartularo L, Kluz T, Cohen L, Shen SS, Costa M. Molecular Mechanisms of Malignant Transformation by Low Dose Cadmium in Normal Human Bronchial Epithelial Cells. PLoS One 2016;11:e0155002. [PMID: 27186882 DOI: 10.1371/journal.pone.0155002] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
22 Chew V, Tow C, Huang C, Bard-Chapeau E, Copeland NG, Jenkins NA, Weber A, Lim KH, Toh HC, Heikenwalder M. Toll-like receptor 3 expressing tumor parenchyma and infiltrating natural killer cells in hepatocellular carcinoma patients. J Natl Cancer Inst. 2012;104:1796-1807. [PMID: 23197495 DOI: 10.1093/jnci/djs436] [Cited by in Crossref: 59] [Cited by in F6Publishing: 54] [Article Influence: 5.9] [Reference Citation Analysis]
23 Holtick U, Scheulen ME, von Bergwelt-Baildon MS, Weihrauch MR. Toll-like receptor 9 agonists as cancer therapeutics. Expert Opin Investig Drugs. 2011;20:361-372. [PMID: 21254877 DOI: 10.1517/13543784.2011.553187] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 2.7] [Reference Citation Analysis]
24 Basith S, Manavalan B, Yoo TH, Kim SG, Choi S. Roles of toll-like receptors in cancer: a double-edged sword for defense and offense. Arch Pharm Res. 2012;35:1297-1316. [PMID: 22941474 DOI: 10.1007/s12272-012-0802-7] [Cited by in Crossref: 117] [Cited by in F6Publishing: 114] [Article Influence: 11.7] [Reference Citation Analysis]
25 Seiffert M, Dietrich S, Jethwa A, Glimm H, Lichter P, Zenz T. Exploiting biological diversity and genomic aberrations in chronic lymphocytic leukemia. Leuk Lymphoma 2012;53:1023-31. [PMID: 22023519 DOI: 10.3109/10428194.2011.631638] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
26 Jiang J, Dong L, Qin B, Shi H, Guo X, Wang Y. Decreased expression of TLR7 in gastric cancer tissues and the effects of TLR7 activation on gastric cancer cells. Oncol Lett 2016;12:631-6. [PMID: 27347192 DOI: 10.3892/ol.2016.4617] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
27 Messaritakis I, Koulouridi A, Sfakianaki M, Vogiatzoglou K, Gouvas N, Athanasakis E, Tsiaoussis J, Xynos E, Mavroudis D, Tzardi M, Souglakos J. The Role of Vitamin D Receptor Gene Polymorphisms in Colorectal Cancer Risk. Cancers (Basel) 2020;12:E1379. [PMID: 32471257 DOI: 10.3390/cancers12061379] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
28 Chiron D, Pellat-Deceunynck C, Maillasson M, Bataille R, Jego G. Phosphorothioate-modified TLR9 ligands protect cancer cells against TRAIL-induced apoptosis. J Immunol 2009;183:4371-7. [PMID: 19734228 DOI: 10.4049/jimmunol.0901436] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
29 Klein JC, Moses K, Zelinskyy G, Sody S, Buer J, Lang S, Helfrich I, Dittmer U, Kirschning CJ, Brandau S. Combined toll-like receptor 3/7/9 deficiency on host cells results in T-cell-dependent control of tumour growth. Nat Commun 2017;8:14600. [PMID: 28300057 DOI: 10.1038/ncomms14600] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
30 Guil-Luna S, Mena R, Navarrete-Sirvent C, López-Sánchez LM, Khouadri K, Toledano-Fonseca M, Mantrana A, Guler I, Villar C, Díaz C, Medina-Fernández FJ, De la Haba-Rodríguez JR, Aranda E, Rodríguez-Ariza A. Association of Tumor Budding With Immune Evasion Pathways in Primary Colorectal Cancer and Patient-Derived Xenografts. Front Med (Lausanne) 2020;7:264. [PMID: 32719800 DOI: 10.3389/fmed.2020.00264] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Arora S, Ahmad S, Irshad R, Goyal Y, Rafat S, Siddiqui N, Dev K, Husain M, Ali S, Mohan A, Syed MA. TLRs in pulmonary diseases. Life Sci 2019;233:116671. [PMID: 31336122 DOI: 10.1016/j.lfs.2019.116671] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 8.7] [Reference Citation Analysis]
32 Wang Y, Weng Y, Shi Y, Xia X, Wang S, Duan H. Expression and functional analysis of Toll-like receptor 4 in human cervical carcinoma. J Membr Biol 2014;247:591-9. [PMID: 24878539 DOI: 10.1007/s00232-014-9675-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
33 Wu H, Gao H, Li A, Xie Y, Jia Z, Yang Z, Zhang H, Zhang Z, Zhang X. Impact of Genetic Variation in TLR4 3'UTR on NSCLC Genetic Susceptibility. J Oncol 2020;2020:7593143. [PMID: 32351566 DOI: 10.1155/2020/7593143] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
34 Shi S, Xu C, Fang X, Zhang Y, Li H, Wen W, Yang G. Expression profile of Toll‑like receptors in human breast cancer. Mol Med Rep 2020;21:786-94. [PMID: 31789409 DOI: 10.3892/mmr.2019.10853] [Cited by in Crossref: 5] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
35 Liu C. Guardian and selective killer: the versatile functions of TLR3 in hepatocellular carcinoma. J Natl Cancer Inst 2012;104:1780-2. [PMID: 23197496 DOI: 10.1093/jnci/djs475] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
36 Gnjatic S, Sawhney NB, Bhardwaj N. Toll-like receptor agonists: are they good adjuvants? Cancer J 2010;16:382-91. [PMID: 20693851 DOI: 10.1097/PPO.0b013e3181eaca65] [Cited by in Crossref: 106] [Cited by in F6Publishing: 58] [Article Influence: 8.8] [Reference Citation Analysis]
37 Słotwiński R, Słotwińska SM. Dysregulation of signaling pathways associated with innate antibacterial immunity in patients with pancreatic cancer. Cent Eur J Immunol 2016;41:404-18. [PMID: 28450804 DOI: 10.5114/ceji.2016.65140] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
38 Zhang Y, Cui Z, Kong H, Xia K, Pan L, Li J, Sun Y, Shi J, Wang L, Zhu Y, Fan C. One-Shot Immunomodulatory Nanodiamond Agents for Cancer Immunotherapy. Adv Mater 2016;28:2699-708. [PMID: 26833992 DOI: 10.1002/adma.201506232] [Cited by in Crossref: 84] [Cited by in F6Publishing: 77] [Article Influence: 14.0] [Reference Citation Analysis]
39 Pu R, Pu M, Huang H, Cui Y. MicroRNA 144 inhibits cell migration and invasion and regulates inflammatory cytokine secretion through targeting toll like receptor 2 in non-small cell lung cancer. Arch Med Sci 2021;17:1028-37. [PMID: 34336030 DOI: 10.5114/aoms.2020.93084] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
40 Xu C, Li H, Yin M, Yang T, An L, Yang G. Osteopontin is involved in TLR4 pathway contributing to ovarian cancer cell proliferation and metastasis. Oncotarget 2017;8:98394-404. [PMID: 29228698 DOI: 10.18632/oncotarget.21844] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
41 Santos-sierra S. Developments in anticancer vaccination: budding new adjuvants. Biological Chemistry 2020;401:435-46. [DOI: 10.1515/hsz-2019-0383] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
42 Yu L, Wang L, Chen S. Endogenous toll-like receptor ligands and their biological significance. J Cell Mol Med. 2010;14:2592-2603. [PMID: 20629986 DOI: 10.1111/j.1582-4934.2010.01127.x] [Cited by in Crossref: 313] [Cited by in F6Publishing: 301] [Article Influence: 28.5] [Reference Citation Analysis]
43 Wang AC, Ma YB, Wu FX, Ma ZF, Liu NF, Gao R, Gao YS, Sheng XG. TLR4 induces tumor growth and inhibits paclitaxel activity in MyD88-positive human ovarian carcinoma in vitro.. Oncol Lett 2014;7:871-7. [PMID: 24527095 DOI: 10.3892/ol.2013.1759] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 3.4] [Reference Citation Analysis]
44 Duval KEA, Vernice NA, Wagner RJ, Fiering SN, Petryk JD, Lowry GJ, Tau SS, Yin J, Houde GR, Chaudhry AS, Hoopes PJ. Immunogenetic effects of low dose (CEM43 30) magnetic nanoparticle hyperthermia and radiation in melanoma cells. Int J Hyperthermia 2019;36:37-46. [PMID: 31795829 DOI: 10.1080/02656736.2019.1627433] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
45 Yue Y, Zhou T, Gao Y, Zhang Z, Li L, Liu L, Shi W, Su L, Cheng B. High mobility group box 1/toll-like receptor 4/myeloid differentiation factor 88 signaling promotes progression of gastric cancer. Tumour Biol 2017;39:101042831769431. [DOI: 10.1177/1010428317694312] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
46 Sorrentino R, Morello S, Forte G, Montinaro A, Vita GD, Luciano A, Palma G, Arra C, Maiolino P, Adcock IM, Pinto A. B Cells Contribute to the Antitumor Activity of CpG-Oligodeoxynucleotide in a Mouse Model of Metastatic Lung Carcinoma. Am J Respir Crit Care Med 2011;183:1369-79. [DOI: 10.1164/rccm.201010-1738oc] [Cited by in Crossref: 48] [Cited by in F6Publishing: 31] [Article Influence: 4.4] [Reference Citation Analysis]
47 Vidya MK, Kumar VG, Sejian V, Bagath M, Krishnan G, Bhatta R. Toll-like receptors: Significance, ligands, signaling pathways, and functions in mammals. Int Rev Immunol 2018;37:20-36. [PMID: 29028369 DOI: 10.1080/08830185.2017.1380200] [Cited by in Crossref: 154] [Cited by in F6Publishing: 150] [Article Influence: 30.8] [Reference Citation Analysis]
48 Pinto A, Morello S, Sorrentino R. Lung cancer and Toll-like receptors. Cancer Immunol Immunother. 2011;60:1211-1220. [PMID: 21789594 DOI: 10.1007/s00262-011-1057-8] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 4.5] [Reference Citation Analysis]
49 Yu L, Wang L, Chen S. REVIEW ARTICLE: Toll-Like Receptors, Inflammation and Tumor in the Human Female Reproductive Tract: TLRS IN FEMALE REPRODUCTIVE TRACT. American Journal of Reproductive Immunology 2009;62:1-8. [DOI: 10.1111/j.1600-0897.2009.00712.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
50 Fouzder C, Mukhuty A, Das S, Chattopadhyay D. TLR Signaling on Protozoan and Helminthic Parasite Infection. In: Rezaei N, editor. Toll-like Receptors. IntechOpen; 2020. [DOI: 10.5772/intechopen.84711] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
51 Uva P, Aurisicchio L, Watters J, Loboda A, Kulkarni A, Castle J, Palombo F, Viti V, Mesiti G, Zappulli V, Marconato L, Abramo F, Ciliberto G, Lahm A, La Monica N, de Rinaldis E. Comparative expression pathway analysis of human and canine mammary tumors. BMC Genomics 2009;10:135. [PMID: 19327144 DOI: 10.1186/1471-2164-10-135] [Cited by in Crossref: 105] [Cited by in F6Publishing: 99] [Article Influence: 8.1] [Reference Citation Analysis]
52 Kim TW, Lee SJ, Oh BM, Lee H, Uhm TG, Min JK, Park YJ, Yoon SR, Kim BY, Kim JW. Epigenetic modification of TLR4 promotes activation of NF-κB by regulating methyl-CpG-binding domain protein 2 and Sp1 in gastric cancer. Oncotarget. 2015; Dec 10. [Epub ahead of print]. [PMID: 26675260 DOI: 10.18632/oncotarget.6549] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 4.8] [Reference Citation Analysis]
53 Ou T, Lilly M, Jiang W. The Pathologic Role of Toll-Like Receptor 4 in Prostate Cancer. Front Immunol 2018;9:1188. [PMID: 29928275 DOI: 10.3389/fimmu.2018.01188] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
54 Sharma Y, Bala K. Role of Toll like receptor in progression and suppression of oral squamous cell carcinoma. Oncol Rev 2020;14:456. [PMID: 32477468 DOI: 10.4081/oncol.2020.456] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
55 Sipos F, Kiss AL, Constantinovits M, Tulassay Z, Műzes G. Modified Genomic Self-DNA Influences In Vitro Survival of HT29 Tumor Cells via TLR9- and Autophagy Signaling. Pathol Oncol Res 2019;25:1505-17. [PMID: 30465163 DOI: 10.1007/s12253-018-0544-z] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
56 Ashour DS. Toll-like receptor signaling in parasitic infections. Expert Review of Clinical Immunology 2015;11:771-80. [DOI: 10.1586/1744666x.2015.1037286] [Cited by in Crossref: 25] [Cited by in F6Publishing: 15] [Article Influence: 3.6] [Reference Citation Analysis]
57 Zhang JJ, Wu HS, Wang L, Tian Y, Zhang JH, Wu HL. Expression and significance of TLR4 and HIF-1α in pancreatic ductal adenocarcinoma. World J Gastroenterol 2010; 16(23): 2881-2888 [PMID: 20556833 DOI: 10.3748/wjg.v16.i23.2881] [Cited by in CrossRef: 53] [Cited by in F6Publishing: 62] [Article Influence: 4.4] [Reference Citation Analysis]
58 Ashour DS, Shohieb ZS, Sarhan NI. Upregulation of Toll-like receptor 2 and nuclear factor-kappa B expression in experimental colonic schistosomiasis. J Adv Res 2015;6:877-84. [PMID: 26644925 DOI: 10.1016/j.jare.2014.08.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
59 Seya T, Azuma M, Matsumoto M. Targeting TLR3 with no RIG-I/MDA5 activation is effective in immunotherapy for cancer. Expert Opinion on Therapeutic Targets 2013;17:533-44. [DOI: 10.1517/14728222.2013.765407] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
60 Kim KH, Jo MS, Suh DS, Yoon MS, Shin DH, Lee JH, Choi KU. Expression and significance of the TLR4/MyD88 signaling pathway in ovarian epithelial cancers. World J Surg Oncol 2012;10:193. [PMID: 22985132 DOI: 10.1186/1477-7819-10-193] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 3.2] [Reference Citation Analysis]
61 Yang S, Liu L, Xu D, Li X. The Relationship of the TLR9 and TLR2 Genetic Polymorphisms with Cervical Cancer Risk: a Meta-Analysis of Case-Control Studies. Pathol Oncol Res 2020;26:307-15. [PMID: 30215163 DOI: 10.1007/s12253-018-0465-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
62 McCall KD, Muccioli M, Benencia F. Toll-Like Receptors Signaling in the Tumor Microenvironment. Adv Exp Med Biol 2020;1223:81-97. [PMID: 32030686 DOI: 10.1007/978-3-030-35582-1_5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
63 Abdi J, Engels F, Garssen J, Redegeld F. The role of Toll-like receptor mediated signalling in the pathogenesis of multiple myeloma. Critical Reviews in Oncology/Hematology 2011;80:225-40. [DOI: 10.1016/j.critrevonc.2010.12.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
64 Dar AA, Patil RS, Chiplunkar SV. Insights into the Relationship between Toll Like Receptors and Gamma Delta T Cell Responses. Front Immunol 2014;5:366. [PMID: 25132835 DOI: 10.3389/fimmu.2014.00366] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 3.8] [Reference Citation Analysis]
65 Mansell A, Jenkins BJ. Dangerous liaisons between interleukin-6 cytokine and toll-like receptor families: A potent combination in inflammation and cancer. Cytokine & Growth Factor Reviews 2013;24:249-56. [DOI: 10.1016/j.cytogfr.2013.03.007] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
66 Sheyhidin I, Nabi G, Hasim A, Zhang RP, Ainiwaer J, Ma H, Wang H. Overexpression of TLR3, TLR4, TLR7 and TLR9 in esophageal squamous cell carcinoma. World J Gastroenterol 2011; 17(32): 3745-3751 [PMID: 21990957 DOI: 10.3748/wjg.v17.i32.3745] [Cited by in CrossRef: 68] [Cited by in F6Publishing: 64] [Article Influence: 6.2] [Reference Citation Analysis]
67 Shi M, Yao Y, Han F, Li Y, Li Y. MAP1S controls breast cancer cell TLR5 signaling pathway and promotes TLR5 signaling-based tumor suppression. PLoS One 2014;9:e86839. [PMID: 24466264 DOI: 10.1371/journal.pone.0086839] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
68 Choi CH, Kang TH, Song JS, Kim YS, Chung EJ, Ylaya K, Kim S, Koh SS, Chung JY, Kim JH, Hewitt SM. Elevated expression of pancreatic adenocarcinoma upregulated factor (PAUF) is associated with poor prognosis and chemoresistance in epithelial ovarian cancer. Sci Rep 2018;8:12161. [PMID: 30111860 DOI: 10.1038/s41598-018-30582-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
69 Grimm M, Kim M, Rosenwald A, Heemann U, Germer CT, Waaga-Gasser AM, Gasser M. Toll-like receptor (TLR) 7 and TLR8 expression on CD133+ cells in colorectal cancer points to a specific role for inflammation-induced TLRs in tumourigenesis and tumour progression. Eur J Cancer. 2010;46:2849-2857. [PMID: 20728343 DOI: 10.1016/j.ejca.2010.07.017] [Cited by in Crossref: 51] [Cited by in F6Publishing: 50] [Article Influence: 4.3] [Reference Citation Analysis]
70 Olbert PJ, Kesch C, Henrici M, Subtil FS, Honacker A, Hegele A, Hofmann R, Hänze J. TLR4- and TLR9-dependent effects on cytokines, cell viability, and invasion in human bladder cancer cells. Urol Oncol 2015;33:110.e19-27. [PMID: 25499923 DOI: 10.1016/j.urolonc.2014.09.016] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
71 Ahmed A, Wang JH, Redmond HP. Silencing of TLR4 increases tumor progression and lung metastasis in a murine model of breast cancer. Ann Surg Oncol 2013;20 Suppl 3:S389-96. [PMID: 22890596 DOI: 10.1245/s10434-012-2595-9] [Cited by in Crossref: 31] [Cited by in F6Publishing: 38] [Article Influence: 3.1] [Reference Citation Analysis]
72 Muccioli M, Benencia F. Toll-like Receptors in Ovarian Cancer as Targets for Immunotherapies. Front Immunol 2014;5:341. [PMID: 25101083 DOI: 10.3389/fimmu.2014.00341] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 4.6] [Reference Citation Analysis]
73 Ayari C, Bergeron A, LaRue H, Ménard C, Fradet Y. Toll-like receptors in normal and malignant human bladders. J Urol 2011;185:1915-21. [PMID: 21421234 DOI: 10.1016/j.juro.2010.12.097] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
74 Dewan MZ, Vanpouille-Box C, Kawashima N, DiNapoli S, Babb JS, Formenti SC, Adams S, Demaria S. Synergy of topical toll-like receptor 7 agonist with radiation and low-dose cyclophosphamide in a mouse model of cutaneous breast cancer. Clin Cancer Res 2012;18:6668-78. [PMID: 23048078 DOI: 10.1158/1078-0432.CCR-12-0984] [Cited by in Crossref: 109] [Cited by in F6Publishing: 59] [Article Influence: 10.9] [Reference Citation Analysis]
75 Messaritakis I, Stogiannitsi M, Koulouridi A, Sfakianaki M, Voutsina A, Sotiriou A, Athanasakis E, Xynos E, Mavroudis D, Tzardi M, Souglakos J. Evaluation of the detection of Toll-like receptors (TLRs) in cancer development and progression in patients with colorectal cancer. PLoS One. 2018;13:e0197327. [PMID: 29883450 DOI: 10.1371/journal.pone.0197327] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
76 Yu L, Wang L, Li M, Zhong J, Wang Z, Chen S. Expression of toll-like receptor 4 is down-regulated during progression of cervical neoplasia. Cancer Immunol Immunother 2010;59:1021-8. [PMID: 20177675 DOI: 10.1007/s00262-010-0825-1] [Cited by in Crossref: 52] [Cited by in F6Publishing: 52] [Article Influence: 4.3] [Reference Citation Analysis]
77 Hua D, Liu MY, Cheng ZD, Qin XJ, Zhang HM, Chen Y, Qin GJ, Liang G, Li JN, Han XF, Liu DX. Small interfering RNA-directed targeting of Toll-like receptor 4 inhibits human prostate cancer cell invasion, survival, and tumorigenicity. Mol Immunol 2009;46:2876-84. [PMID: 19643479 DOI: 10.1016/j.molimm.2009.06.016] [Cited by in Crossref: 69] [Cited by in F6Publishing: 65] [Article Influence: 5.3] [Reference Citation Analysis]
78 Kosik-Bogacka DI, Wojtkowiak-Giera A, Kolasa A, Salamatin R, Jagodzinski PP, Wandurska-Nowak E. Hymenolepis diminuta: analysis of the expression of Toll-like receptor genes (TLR2 and TLR4) in the small and large intestines of rats. Exp Parasitol 2012;130:261-6. [PMID: 22209940 DOI: 10.1016/j.exppara.2011.12.002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
79 Yu L, Pham Q, Yu LL, Wang TTY. Modulation of CXC-motif chemokine receptor 7, but not 4, expression is related to migration of the human prostate cancer cell LNCaP: regulation by androgen and inflammatory stimuli. Inflamm Res 2020;69:167-78. [PMID: 31865399 DOI: 10.1007/s00011-019-01305-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
80 Galluzzi L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G. Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology 2012;1:699-716. [PMID: 22934262 DOI: 10.4161/onci.20696] [Cited by in Crossref: 153] [Cited by in F6Publishing: 148] [Article Influence: 153.0] [Reference Citation Analysis]
81 Rayburn ER, Ezell SJ, Zhang R. Anti-Inflammatory Agents for Cancer Therapy. Mol Cell Pharmacol 2009;1:29-43. [PMID: 20333321 DOI: 10.4255/mcpharmacol.09.05] [Cited by in Crossref: 177] [Cited by in F6Publishing: 169] [Article Influence: 13.6] [Reference Citation Analysis]
82 Braganhol E, Kukulski F, Lévesque SA, Fausther M, Lavoie EG, Zanotto-Filho A, Bergamin LS, Pelletier J, Bahrami F, Ben Yebdri F, Fonseca Moreira JC, Battastini AM, Sévigny J. Nucleotide receptors control IL-8/CXCL8 and MCP-1/CCL2 secretions as well as proliferation in human glioma cells. Biochim Biophys Acta 2015;1852:120-30. [PMID: 25445541 DOI: 10.1016/j.bbadis.2014.10.014] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 4.6] [Reference Citation Analysis]
83 Paramjot, Khan NM, Kapahi H, Kumar S, Bhardwaj TR, Arora S, Mishra N. Role of polymer–drug conjugates in organ-specific delivery systems. Journal of Drug Targeting 2015;23:387-416. [DOI: 10.3109/1061186x.2015.1016436] [Cited by in Crossref: 10] [Article Influence: 1.4] [Reference Citation Analysis]
84 Gao SL, Chen YD, Yue C, Chen J, Zhang LF, Wang SM, Zuo L. -196 to -174del, rs4696480, rs3804099 polymorphisms of Toll-like receptor 2 gene impact the susceptibility of cancers: evidence from 37053 subjects. Biosci Rep 2019;39:BSR20191698. [PMID: 31710083 DOI: 10.1042/BSR20191698] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
85 Weng Y, Wang Y, Shi Y, Zhou W, Wang H, Wang C. TLR9 expression and its role in chemosensitivity to DDP in human cervical cancer cells in vitro. J Huazhong Univ Sci Technolog Med Sci 2011;31:550. [PMID: 21823020 DOI: 10.1007/s11596-011-0488-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
86 Pal S, Bhattacharjee A, Ali A, Mandal NC, Mandal SC, Pal M. Chronic inflammation and cancer: potential chemoprevention through nuclear factor kappa B and p53 mutual antagonism. J Inflamm (Lond) 2014;11:23. [PMID: 25152696 DOI: 10.1186/1476-9255-11-23] [Cited by in Crossref: 70] [Cited by in F6Publishing: 70] [Article Influence: 8.8] [Reference Citation Analysis]